M
Mark Laughlin
Researcher at Schering-Plough
Publications - 21
Citations - 2462
Mark Laughlin is an academic researcher from Schering-Plough. The author has contributed to research in topics: Posaconazole & Pegylated interferon. The author has an hindex of 14, co-authored 21 publications receiving 2389 citations.
Papers
More filters
Journal ArticleDOI
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
Karen L. Lindsay,Christian Trepo,Tobias Heintges,Mitchell L. Shiffman,Stuart C. Gordon,John C. Hoefs,Eugene R. Schiff,Zachary Goodman,Mark Laughlin,Ruji Yao,Janice K. Albrecht +10 more
TL;DR: PegIntron alfa‐2b maintained the clinical efficacy of interferon alfa'2b while preserving its safety profile and increased virologic response rates after treatment and after follow‐up, as compared with interferons alfa'; however, the higher rate of virolic response during treatment with 1.5 μg/kg peginterferonAlfa‐ 2b in patients infected with genotype 1 and high viral levels warrants further evaluation.
Journal ArticleDOI
Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.
TL;DR: The suspension formulation of posaconazole was associated with enhanced systemic exposure and increased relative bioavailability compared with the tablet, and food substantially enhanced the rate and extent of posconazole absorption in healthy subjects.
Journal ArticleDOI
Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults
TL;DR: The long elimination-phase half-life of posaconazole supports once- or twice-daily dosing in clinical trials; however, additional studies are required to determine if further division of the dose will enhance exposure.
Journal ArticleDOI
Oral Bioavailability of Posaconazole in Fasted Healthy Subjects: Comparison Between Three Regimens and Basis for Clinical Dosage Recommendations
TL;DR: It is suggested that divided daily dose administration (every 12 or 6 hours) significantly increases posaconazole exposure under fasted conditions and significantly increases the bioavailability fraction among regimens.
Journal ArticleDOI
Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study.
TL;DR: Results suggest that posaconazole may have an improved and more narrow drug interaction profile (CYP3A4 only) compared with other triazoles.